Literature DB >> 33428063

EGFR Protein Expression Relates with Tumor Histology, Methylation Status of EGFR and HPV16 E6 Viral Load in Oropharyngeal Carcinoma.

Yo Suzuki1,2, Yuki Fukumura3, Miki Asahina2, Mitsuhisa Fujimaki1, Shinichi Ohba1, Fumihiko Matsumoto1, Isao Kurahayashi2, Takashi Yao2, Katsuhisa Ikeda1.   

Abstract

The epidermal growth factor receptor (EGFR) pathway is important in tumorigenesis of oropharyngeal carcinoma (OPC). However, the molecular mechanisms contributing to EGFR expression in OPC are not well-known. To detect relating factors and clinicopathological impact of EGFR protein expression in OPC, gene amplification/loss, point mutations including synonymous mutations, and promoter methylation of EGFR, and the viral genome load of human papillomavirus type 16 (HPV16)-E5, -E6, and -E7, after extracting HPV16-related OPCs with qPCR of HPV16-E6 and E7, were investigated in 74 OPC surgical cases, including 52 HPV-related (HPV-OPC) and 22 HPV-unrelated (nHPV-OPC). Immunohistochemical (IHC) data of EGFR expression (high, weak, and negative), validated by the qPCR of EGFR mRNA, were compared with molecular, viral, and clinicopathological data of patients. All nHPV-OPC cases were EGFR-IHC-high, whereas 21.2%, 65.4%, and 13.5% of HPV-OPC cases showed EGFR-IHC-high, -weak, -negative (p < 0.01), respectively. In HPV-OPC cases, EGFR-IHC-weak/negative status was related to promoter methylation of EGFR (p = 0.009), but not with gene amplification/loss or the point mutation of EGFR and was more often seen in HPV16-OPC cases (p = 0.049). Among HPV16-OPC cases, EGFR-IHC-weak/negative was related to high E6 expression. EGFR protein-loss was related to the tumor histology of non-keratinizing squamous cell carcinoma (SCC) (p = 0.035) but not with patient prognosis. In conclusion, decreased EGFR protein expression was more frequent in HPV-OPC than in nHPV-OPC and was related to EGFR methylation, infection of HPV16, and the viral genome load of HPV16-E6. Clinicopathologically, it was related to the tumor histology of non-keratinizing SCC.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  E5; E6; E7; Epidermal growth factor receptor; Human papilloma virus; Methylation; Non-keratinizing squamous cell carcinoma; Oropharyngeal carcinoma

Mesh:

Substances:

Year:  2021        PMID: 33428063      PMCID: PMC8385027          DOI: 10.1007/s12105-020-01261-w

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  44 in total

1.  Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

Authors:  Christine H Chung; Kim Ely; Loris McGavran; Marileila Varella-Garcia; Joel Parker; Natalie Parker; Carolyn Jarrett; Jesse Carter; Barbara A Murphy; James Netterville; Brian B Burkey; Robert Sinard; Anthony Cmelak; Shawn Levy; Wendell G Yarbrough; Robbert J C Slebos; Fred R Hirsch
Journal:  J Clin Oncol       Date:  2006-09-01       Impact factor: 44.544

2.  Graphene nanoribbons elicit cell specific uptake and delivery via activation of epidermal growth factor receptor enhanced by human papillomavirus E5 protein.

Authors:  Sayan Mullick Chowdhury; Prady Manepalli; Balaji Sitharaman
Journal:  Acta Biomater       Date:  2014-06-27       Impact factor: 8.947

3.  Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis.

Authors:  Feng Wang-Johanning; Danielle W Lu; Yueying Wang; Martin R Johnson; Gary L Johanning
Journal:  Cancer       Date:  2002-04-15       Impact factor: 6.860

4.  Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.

Authors:  Jong Woo Lee; Young Hwa Soung; Su Young Kim; Hyo Kyung Nam; Won Sang Park; Suk Woo Nam; Min Sik Kim; Dong Il Sun; Youn Soo Lee; Ja June Jang; Jung Young Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

5.  Differential response rates to irradiation among patients with human papillomavirus positive and negative oropharyngeal cancer.

Authors:  Allen M Chen; Judy Li; Laurel A Beckett; Talia Zhara; Gregory Farwell; Derick H Lau; Regina Gandour-Edwards; Andrew T Vaughan; James A Purdy
Journal:  Laryngoscope       Date:  2012-09-24       Impact factor: 3.325

6.  Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.

Authors:  Takahide Taguchi; Mamoru Tsukuda; Yukari Imagawa-Ishiguro; Yasumasa Kato; Daisuke Sano
Journal:  Oncol Rep       Date:  2008-01       Impact factor: 3.906

7.  Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis.

Authors:  Jorge S Reis-Filho; Fernanda Milanezi; Silvia Carvalho; Pete T Simpson; Dawn Steele; Kay Savage; Maryou B K Lambros; Emilio M Pereira; Jahn M Nesland; Sunil R Lakhani; Fernando C Schmitt
Journal:  Breast Cancer Res       Date:  2005-10-25       Impact factor: 6.466

Review 8.  Current trends in the etiology and diagnosis of HPV-related head and neck cancers.

Authors:  Ryan C Chai; Duncan Lambie; Mukesh Verma; Chamindie Punyadeera
Journal:  Cancer Med       Date:  2015-02-01       Impact factor: 4.452

9.  Comprehensive genomic characterization of head and neck squamous cell carcinomas.

Authors: 
Journal:  Nature       Date:  2015-01-29       Impact factor: 49.962

10.  Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer.

Authors:  Jongseung Kim; Bu Kyung Kim; Dongsoo Jeon; Chae Hyeong Lee; Ju-Won Roh; Joo-Young Kim; Sang-Yoon Park
Journal:  Cancer Res Treat       Date:  2019-08-28       Impact factor: 4.679

View more
  1 in total

Review 1.  Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes.

Authors:  Nayiri M Kaissarian; Douglas Meyer; Chava Kimchi-Sarfaty
Journal:  J Natl Cancer Inst       Date:  2022-08-08       Impact factor: 11.816

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.